Expertise in
9
conditions

Dr. Rene Y. Mcnall-Knapp

Hematology
Oklahoma Children's Hospital Ou Health-Jimmy Everest Center
1200 Childrens Ave # 10A, 
Oklahoma City, OK 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
9
conditions
Oklahoma Children's Hospital Ou Health-Jimmy Everest Center
1200 Childrens Ave # 10A, 
Oklahoma City, OK 

Overview

Rene Mcnall-Knapp is a Hematologist practicing medicine in Oklahoma City, Oklahoma.

Dr. Mcnall-Knapp is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 82 clinical trials. Dr. Mcnall-Knapp is currently accepting new patients.

Specialties

Hematology

Licenses

Pediatric Hematology-Oncology in OK

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Oklahoma Children's Hospital Ou Health-Jimmy Everest Center
1200 Childrens Ave # 10A, Oklahoma City, OK 73104

Additional Areas of Focus

Dr. Mcnall-Knapp has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

82 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
View 9 Less Clinical Trials

36 Total Publications

Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma.
Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma.
Journal: CNS oncology
Published: October 03, 2025
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.3 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sami Ibrahimi is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Ibrahimi is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ibrahimi is currently accepting new patients.

Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.3 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Asch is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Asch is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Asch is currently accepting new patients.

Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Referral may be required

SSM Health Cancer Care

1000 N. Lee Ave., 
Oklahoma City, OK 
 (1.5 miles away)
405-228-7100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Board certified in medical oncology, Todd Kliewer, MD is a physician in the Frank C. Love Cancer Institute at SSM Health St. Anthony Hospital - Oklahoma City and SSM Health Cancer Care in Midwest City. He treats patients in two convenient locations in Midtown Oklahoma City and Midwest City. Dr. Kliewer is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Breast Cancer. Dr. Kliewer is board certified in Oklahoma State Board Of Medical Licensure & Supervision, American Board Of Internal Medicine/Medical Oncology , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . Dr. Kliewer is currently accepting new patients.

Frequently Asked Questions about Dr. Rene Y. Mcnall-Knapp

How do I make an appointment with Dr. Rene Y. Mcnall-Knapp?

You can book an appointment with Dr. Rene Y. Mcnall-Knapp by calling their office at 405-271-4412. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rene Y. Mcnall-Knapp a top-rated expert for Neurofibromatosis Type 1 (NF1)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rene Y. Mcnall-Knapp is classified as an Advanced expert for Neurofibromatosis Type 1 (NF1), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rene Y. Mcnall-Knapp specialize in?

While Dr. Rene Y. Mcnall-Knapp is a Hematology, they have specific expertise in Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rene Y. Mcnall-Knapp participate in research or clinical trials?

Yes. Dr. Rene Y. Mcnall-Knapp has published 36 articles and abstracts on conditions like Neurofibromatosis Type 1 (NF1). You can view a list of Dr. Rene Y. Mcnall-Knapp's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rene Y. Mcnall-Knapp accept my insurance?

Dr. Rene Y. Mcnall-Knapp accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 405-271-4412 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcnall-Knapp's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile